NCT01891968View on ClinicalTrials.gov

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 7, 2013

Primary Completion Date

January 18, 2017

Study Completion Date

January 18, 2017

Conditions
Leukemia
Interventions
DRUG

Bortezomib

1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER